SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte ...

B-cell lymphoma in the 3L+ setting83% overall response and 61% complete response rates in cohort comprised predominantly of ...

London, UK - 9th December 2025. Actimed Therapeutics Ltd ('Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system ...

The ASH oral presentation today reports data from the ongoing dose escalation and dose expansion parts of the CARDINAL study of TERN-701 in patients with previously treated CML. As of the September 13 ...

Detailed price information for Briacell Therapeutics Corp (BCTX-Q) from The Globe and Mail including charting and trades.

Study conducted at US sites evaluates LumeeTM in peripheral artery disease (PAD) patients BERKELEY, Calif, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), ...

Mayo Clinic Labs CEO explains how healthcare's data revolution reshapes clinical diagnostics and accelerates medical research.

Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients dosed with 100 million cellsAll patients show deep ...

Fulcrum Therapeutics To Host Investor Event To Review New Clinical Data From The PIONEER Trial Of Pociredir In Sickle Cell Disease On December 7, 2025. CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) ...

Based on Stoke Therapeutics’ preliminary estimates, which scaled annual incidence to prevalence using country-specific live birth rates over the past 85 years and adjusted for Dravet-specific ...

ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting ...